HK Stock Market Move | REMEGEN (09995) surged up by over 5%, the application for the listing of RC288 injection was accepted, institutions are optimistic about its global potential.

REMEGEN (09995) rose by more than 5%, rising by 4.41% as of the time of publication, reaching 90 Hong Kong dollars with a trading volume of 152 million Hong Kong dollars. In terms of news, REMEGEN's application for the listing of REMEGEN RC288 injection has been accepted by the NMPA. RC288 is a PSMA/B7H3 ADC independently developed by REMEGEN, and in preclinical studies, the drug has shown excellent anti-tumor activity and safety. Guotai Haitong released a research report stating that REMEGEN will enter a new growth phase starting in 2026, mainly benefiting from the listing and entry into medical insurance for new indications of RC18, RC48, and RC28; overseas indications for RC48 and RC18 will gradually be launched for sales starting in 2027, bringing in sales royalties for the company; the company has started licensing out multiple assets since 2025, with initial payments and milestones to be confirmed in the coming years, strengthening the financial statements; the newly entered global FIC pipeline CDCP1 ADC RC278 and B7H3/PSMA ADC RC288 have the potential for global competitiveness, possibly bringing opportunities for licensing out.